Investigational Drug Information for GS-4997
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for GS-4997?
GS-4997 is an investigational drug.
There have been 9 clinical trials for GS-4997.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 30th 2017.
The most common disease conditions in clinical trials are Fatty Liver, Non-alcoholic Fatty Liver Disease, and Diabetic Nephropathies. The leading clinical trial sponsors are Gilead Sciences, HepQuant, LLC, and [disabled in preview].
There are twenty-eight US patents protecting this investigational drug and five hundred and thirty-seven international patents.
Summary for GS-4997
| US Patents | 28 |
| International Patents | 537 |
| US Patent Applications | 207 |
| WIPO Patent Applications | 184 |
| Japanese Patent Applications | 21 |
| Clinical Trial Progress | Phase 2 (2017-01-30) |
| Vendors | 54 |
Recent Clinical Trials for GS-4997
| Title | Sponsor | Phase |
|---|---|---|
| Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | Gilead Sciences | Phase 3 |
| Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Gilead Sciences | Phase 3 |
| Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH) | Gilead Sciences | Phase 2 |
Clinical Trial Summary for GS-4997
Top disease conditions for GS-4997
Top clinical trial sponsors for GS-4997
US Patents for GS-4997
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GS-4997 | See Plans and Pricing | Fused heterocyclic compounds as CaM kinase inhibitors | Gilead Sciences, Inc. (Foster City, CA) | See Plans and Pricing |
| GS-4997 | See Plans and Pricing | ASK1 inhibitor compounds and uses thereof | SEAL ROCK THERAPEUTICS, INC. (Seattle, WA) | See Plans and Pricing |
| GS-4997 | See Plans and Pricing | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | Gilead Apollo, LLC (Foster City, CA) | See Plans and Pricing |
| GS-4997 | See Plans and Pricing | Methods of treating liver disease | Gilead Sciences, Inc. (Foster City, CA) | See Plans and Pricing |
| GS-4997 | See Plans and Pricing | Cyclobutyl-imidazolidinone compounds | ELI LILLY AND COMPANY (Indianapolis, IN) | See Plans and Pricing |
| GS-4997 | See Plans and Pricing | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | Gilead Apollo, LLC (Foster City, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GS-4997
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GS-4997 | Argentina | AR110252 | 2036-11-30 | See Plans and Pricing |
| GS-4997 | European Patent Office | EP3548495 | 2036-11-30 | See Plans and Pricing |
| GS-4997 | Spain | ES2861382 | 2036-11-30 | See Plans and Pricing |
| GS-4997 | Taiwan | TW201831487 | 2036-11-30 | See Plans and Pricing |
| GS-4997 | Taiwan | TWI651325 | 2036-11-30 | See Plans and Pricing |
| GS-4997 | World Intellectual Property Organization (WIPO) | WO2018102384 | 2036-11-30 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
